Adma Biologics CEO Adam Grossman sells 1.03 million in stock
| ADMA Stock | USD 21.83 0.01 0.05% |
About 64% of ADMA Biologics' investor base is looking to short. The analysis of overall sentiment of trading ADMA Biologics stock suggests that many investors are alarmed at this time. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
Adma Biologics CEO Adam Grossman sells 1.03 million in stock
Read at investing.com
 |
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
ADMA Biologics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
| FATE | Fate Therapeutics | 18.28 | ||||
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| CRBU | Caribou Biosciences | 8.91 | ||||
| MCRB | Seres Therapeutics | 4.55 | ||||
| SANA | Sana Biotechnology | 4.08 | ||||
| IBIO | Ibio | 3.54 | ||||
| TFFP | Tff Pharmaceuticals | 3.33 | ||||
| CDTX | Cidara Therapeutics | 3.11 | ||||
| ETNB | 89bio | 2.70 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
| VXRT | Vaxart | 1.67 | ||||
| PLRX | Pliant Therapeutics | 1.42 | ||||
| STOK | Stoke Therapeutics | 1.19 | ||||
| PLX | Protalix Biotherapeutics | 0.60 | ||||
| AKBA | Akebia Ther | 0.49 | ||||
| INMB | INmune Bio | 0.20 | ||||
| BCRX | BioCryst Pharmaceuticals | 0.13 | ||||
| RCUS | Arcus Biosciences | 0.06 | ||||
| ATRA | Atara Biotherapeutics | 0.65 | ||||
| ANTX | AN2 Therapeutics | 1.44 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
| ACLX | Arcellx | 2.08 | ||||
| TNXP | Tonix Pharmaceuticals | 5.00 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |